Why Amgen (AMGN) is a Top Value Stock for the Long-Term

Amgen (AMGN), a prominent biotech company, is highlighted as a potential value stock despite competitive pressures on older drugs, with growth driven by newer blockbuster products. The company currently holds a Zacks Rank #3 (Hold) and strong B scores for both Value and VGM, underpinned by an attractive forward P/E ratio of 12.94. Analyst sentiment is positive, with 12 analysts revising their FY2025 earnings estimates upwards in the last 60 days, raising the consensus to $21.10 per share, complemented by an average earnings surprise of +11.8%.

Analysis

Amgen (AMGN) presents a compelling case for value-oriented investors, though it carries a neutral Zacks Rank of #3 (Hold). The company's portfolio is in a state of transition, with sales from legacy blockbuster drugs like Epogen and Enbrel declining due to biosimilar and branded competition. However, this is being offset by growth from newer products such as Prolia and Xgeva. The stock's valuation appears attractive, highlighted by a forward P/E ratio of 12.94, which underpins its 'B' grade for Value in the Zacks Style Scores. Analyst sentiment for the medium term is strengthening, evidenced by 12 upward earnings estimate revisions for fiscal year 2025 within the last 60 days. This has lifted the FY2025 consensus estimate by $0.26 to $21.10 per share. Furthermore, Amgen has a demonstrated history of outperforming expectations, boasting an average positive earnings surprise of 11.8%.

Key Decisions for Investors

• Given the attractive forward P/E of 12.94 and positive earnings revisions for FY2025, value-focused investors may find the current valuation an opportune entry point, despite the neutral 'Hold' rating.
• Investors should closely monitor the sales trajectory of Amgen's growth products to ensure they are effectively offsetting the well-documented revenue declines from its legacy portfolio facing competitive pressures.
• The consistent history of an 11.8% average earnings surprise suggests a pattern of conservative guidance or underestimated performance, which could present opportunities around future earnings announcements.
• The trend of upward analyst estimate revisions for FY2025 is a key leading indicator to watch, as its continuation could foreshadow a potential ratings upgrade and improved market sentiment.